The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
EmmanouilidesC., SfakiotakiG., AndroulakisN.Front-line bevacizumab in combination with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer.2007; 7(1): 91–97.
2.
GiantonioB.J., CatalanoP.J., MeropolN.J.Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol.2007; 25(12): 1539–1544.
3.
SaltzL.B., ClarkeS., Diaz-RubioE.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol.2008; 26(12): 2013–2019.
4.
BirA., TanW., WildingG.E., LombardoJ., FakihM.G.5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. Oncology.2007; 72(1-2): 4–9.
5.
HochsterH.S., HartL.L., RamanathanR.K.Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol.2008; 26(21): 3523–3529.
6.
AllegraC.J., YothersG., O'ConnellM.J.Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol.2009; 27(20): 3385–3390.
7.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology. Colon cancer. v.3.2010. NCCN Web site. http://www.nccn.org. Accessed June 3, 2010.
8.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology. Rectal cancer. v.3.2010. NCCN Web site. http://www.nccn.org. Accessed June 3, 2010.
9.
National Comprehensive Cancer Network. NCCN clinical practice guidelines. Antiemesis. v.2.2010. Available at. http://www.nccn.org. Accessed June 5, 2010.
10.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology Guideline for Antiemetics in Oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
11.
Multinational Association of Supportive Care in Cancer antiemetic guidelines. Multinational Association of Supportive Care in Cancer Web site. www.mascc.org. Published March 2008. Accessed June 5, 2010.
12.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
13.
GammonD., BhargavaP., McCormickM.J.Hypersensitivity reactions to oxaliplatin and the application of a desensitization protocol. The Oncologist.2004; 9(5): 546–549.
14.
SyrigouE.I., KarapanagiotouE.M., AlamaraC.V., BouraP.G., SaifM.W., SyrigosK.N.Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer.2009; 8(2): 106–109.
15.
KimB.H., BradleyT., TaiJ., BudmanD.R.Hypersensitivity to oxaliplatin an investigation of incidence and risk factors and literature review. Oncology.2009; 76(4): 231–238.
16.
PolyzosA., TsavarisN., GogasH.Clinical features of hypersensitivity reactions to oxaliplatin 10-year experience. Oncology.2009; 76(1): 36–41.
17.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
18.
National Comprehensive Cancer Network.NCCN clinical practice guidelines in Oncology. Myeloid growth factors. v.1.2010. http://www.nccn.org. Accessed June 14, 2010.
19.
MarounJ.A., AnthonyL.B., BlaisN.Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on chemotherapy-induced diarrhea. Curr Oncol.2007; 14(1): 13–20.
20.
BensonA.B., AjaniJ.A., CatalanoR.B.Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol.2004; 22(14): 2918–2926.
21.
Eloxatin [product information].Bridgewater, NJ: sanofi-aventis US LLC, 2009.
22.
GamelinE., GamelinL., BossiL.Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol.2002; 29(5 suppl 15): 21–33.
KurnialiP.C., LuoL.G., WeitbergA.B.Role of calcium/magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients. Oncology.2010; 24(3): 289–292.
25.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
26.
TakimotoC.H., GrahamM.A., LockwoodG.Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res.2007; 13(16): 4832–4839.
27.
Avastin [product information].South San Francisco, CA: Genentech, Inc, 2009.
28.
FloydJ., MirzaI., SachsB., PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33: 50–67.
29.
SynoldT.W., TakimotoC.H., DoroshowJ.H.Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res.2007; 13(12): 3660–3666.
30.
SoubraneO., BrouquetA., ZalinskiS.Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases. Ann Surg.2010; 251(3): 454–460.
